SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 206.84+2.8%Nov 18 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (11376)11/18/1997 4:25:00 PM
From: Andreas Helke  Read Replies (4) of 32384
 
If you ever wondered how Ligand managed to get almost universal
strong buys as analyst ratings I think I have found one of the
reasons. The current going rate for Ligand shares is about 1/3
of fair value.

On the PairGain thread Cyrus Mashhoodi posted a formula for
valuating development stage biotechs that he got from an
investment seminar.
techstocks.com

"Here is the M formula for biotech/Medtech

M score;

M = ratio of market Cap to total last 5 yrs of R & D

5X is Cheap
7-8X is fair
10X is pretty full
3X is venture capital pricing
Less than 3 is steal"

Now lets apply this to Ligand. After some digging I found the R&D
numbers in Ligands latest 10K filing.

With 28720940 shares outstanding and 5 year R&D of 166.856 millions
we get the following list

Price/share Market Cap Marketcap/5year R&D
14 402,92 2,4147479

below 3 a steal
17,4 501 3 venture capital pricing
29,0 834 5 cheap
40,6 1168 7 fair
46,4 1335 8 fair
58,0 1669 10 pretty full

Ligand never managed to get even to a cheap valuation and can only
be called a steal at current prices. And the best biotech pipeline
is included in the deal for free. I think I have to put Ligand back
on my buy list despite of already owning a portfolio that is
overweight in Ligand.

Andreas
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext